Fact Sheet 9M 2025 | Sartorius Stedim Biotech

Company profile

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions and focus on single-use technologies are supporting biopharma companies around the world to develop and produce drugs safely, timely and economically. Head-quartered in Aubagne, France, Sartorius Stedim Biotech employs around 9,900 people in more than 30 countries.

Investment Highlights

1. Focus on the high-growth biopharma market
2. Broad and differentiating product offering
3. Strong global presence
4. High share of recurring business; significant market entry barriers
5. Proven track record with alliances and acquisitions;
6. High continuity with respect to customer base, employees and management

Key Figures

in millions of € unless otherwise specified

	9M 2025	Δ in %	9M 2024	FY 2024	FY 2023	FY 2022
Sales revenue (% Δ in const. fx)	**2,195.3**	+10.2	2,028.7	2,780.0	2,775.5	3,492.7
Underlying EBITDA[1]	**683.1**	+21.0	564.7	779.0	785.4	1,221.4
Underlying EBITDA margin[1] in %	**31.1**	+3.3 pp	27.8	28.0	28.3	35.0
Underlying net profit[2]	**319.5**	+34.3	238.0	337.5	385.9	796.6
Underlying Earnings per share[2] in €	**3.28**	+33.3	2.46	3.49	4.19	8.64
Equity ratio[3] in %	**51.7**	+2.4 pp	49.3	48.7	34.6	49.6
Ratio net debt to underlying EBITDA[1,4]	**2.5**	-	3.1	2.8	4.5	0.8

1 Earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items
2 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate
3 Equity in relation to the balance sheet total
4 Quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period
Figures are not audited or reviewed.

Sales and Earnings Development



Sales Revenue by Region 2024



Underlying Earnings per Share[1] in €



1 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.

Updated FY 2025 Guidance

	Updated FY 2025 Guidance[1]
Sales revenue growth[2] (in %)	+ ~9%
Underlying EBITDA margin[3]	~31%
Capex ratio	~13% (unchanged)
Net debt/ul. EBITDA[3,4]	Approx. 2.5 (unchanged)

1 Organic, in constant currency; 2 Including effect of tariff surcharges: around 1% uplift to sales revenue; technical margin dilution of around 50 bps; 3 Underlying = excluding extraordinary items; 4 Quotient of net debt and underlying EBITDA over the past 12 months

Fact Sheet 9M 2025 | Sartorius Stedim Biotech

Strategy

- Positioned as a total solution provider for the biopharma industry with a product portfolio covering nearly all steps of the customers' production processes
- Global leading positions in key technology platforms; e.g. process filtration, fluid management, fermentation and membrane chromatography
- One of the widest portfolios in the industry with a clear focus on single-use technologies such as filters, bags and cell culture media
- Regionally focused on gaining market share in North America and leveraging our strong market growth in Asia
- Continuous expansion through complementary acquisitions and alliances

Facts about the Share

Ticker symbol: DIM
Ticker symbol Bloomberg: DIM:FP
Ticker symbol Reuters: STDM.P
ISIN: FR0013154002
Liquidity provider: Gilbert Dupont
Stock exchange: Euronext Paris
Market segment: Local Securities – Compartement A (Large Caps)
Indexes:

- SBF 120
- CAC Next 20
- CAC Large 60
- CAC HEALTH CARE
- STOXX Europe 600
- MSCI France

Sartorius Stedim Biotech Share (indexed)

October 1, 2024, to September 30, 2025



Shareholder Structure

September 30, 2025



Financial calendar

March 24, 2026
Annual Shareholder Meeting in Aubagne

Contact

Petra Müller
Head of Investor Relations
Tel.: +49.551.308.6035
Email: petra.mueller2@sartorius.com